Johnson & Johnson Publishes Results of COVID-19 Single Shot Vaccine in NEJM

Shots:

• The P-III ENSEMBLE trial involves assessing COVID-19 vaccine vs PBO in 43,783 enrolled participants aged ≥18yrs. with both mod. and sev. COVID-19 disease
• The trial met all 1EP & 2EPs i.e 85% efficacy in preventing disease, vaccine efficacy was consistent against symptomatic infection including in South Africa and Brazil that showed a high prevalence of SARS-CoV-2 variants
• Additionally, the trial met its co-1EPs of protecting against mod. to sev. COVID-19 that showed 67% efficacy @14days and 66 % efficacy @28days after vaccination. The vaccine demonstrated efficacy as early as 7days after vaccination, with efficacy continuing to increase 8wks. post-vaccination

Click here to­ read full press release/ article | Ref: J&J | Image: Market Watch